The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Motif Bio To Raise GBP600,000 Via Placing To Fund Major Restructure

Wed, 02nd Oct 2019 11:59

(Alliance News) - Motif Bio PLC on Wednesday said it intends to raise GBP600,000 through a 142.9 million share placing priced at 0.42 pence per share in order to fund its restructuring programme.

Shares in Motif were up 13% at 0.68p in London in late morning trade.

Motif will be holding a general meeting where shareholders will vote on the winding down or disposal of Motif's US subsidiary, Motif Biosciences Inc, and on the issue of placing shares at less than their 1 pence per share nominal value.

The placing is subject to the passing of these resolutions, as well as resolutions to make changes to Motif's articles of association and renew the firm's authority so that it can grant a warrant over 20% of it share capital to Hercules Capital Inc.

In 2017, Motif agreed up to USD20 million of debt financing from Hercules in two tranches. Motif drew down the first USD15.0 million tranche but did not meet the milestones for the second tranche of USD5.0 million. This was amended in February 2019 and in March the firm made USD7.5 million of early repayments.

A new deal has now been agreed, and was announced in its half-year report on Monday. Should shareholders approve a new agreement between the two companies, it has been decided that Hercules will relinquish its loan guarantee from Motif and relieve future obligations. Motif Biosciences Inc will then wind down operations and hire an advisor so it can sell its assets, including antibiotic iclaprim, ideally selling the drug to a firm who would commercialise it.

Hercules will then be given a perfected security interest in all Motif Biosciences Inc's intellectual property as well as a warrant for another 20% of Motif's shares an a 5 pence per share exercise price.

As a result, Motif would be "relieved of the liability and guarantee for the Hercules loan of approximately USD6.9 million".

Following this arrangement, Motif will become a cash shell under AIM rule 15, giving it six months to make a reverse acquisition or have its shares cancelled.

Should the capital raise not go ahead and the deal fail to gain shareholder support, then Motif will be forced to cease its operations and its shares would be suspended.

SP Angel Corporate Finance LLP is acting as bookrunner on the conditional placing.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
1 Jun 2020 11:16

UK TRADING UPDATE SUMMARY: Fuller Smith & Turner Gets GBP100 Million

UK TRADING UPDATE SUMMARY: Fuller Smith & Turner Gets GBP100 Million

Read more
5 May 2020 10:58

Motif Bio Raises GBP650,000 To Strengthen Cash Position

Motif Bio Raises GBP650,000 To Strengthen Cash Position

Read more
5 May 2020 09:17

Motif Bio raises ?0.65m as it hunts for reverse takeover opportunity

(Sharecast News) - Motif Bio, which has been reclassified as an AIM rule 15 cash shell, has raised a total of ?0.65m before expenses via a placing, it announced on Tuesday, through the issue of 162,500,000 ordinary shares with an institutional investor at a price of 0.4p each.

Read more
4 May 2020 15:42

UK EXECUTIVE CHANGE SUMMARY: Scapa Healthcare, Industrial Heads Resign

UK EXECUTIVE CHANGE SUMMARY: Scapa Healthcare, Industrial Heads Resign

Read more
14 Apr 2020 17:12

Motif Bio Notes Hike In Share Price, Still Waiting For Sale Of Assets

Motif Bio Notes Hike In Share Price, Still Waiting For Sale Of Assets

Read more
19 Mar 2020 14:51

Motif Bio Still Seeks To Make Acquisition As Working Capital Dwindles

Motif Bio Still Seeks To Make Acquisition As Working Capital Dwindles

Read more
18 Mar 2020 15:33

Motif Bio struggling to find reverse takeover opportunity

(Sharecast News) - Motif Bio updated the market on its corporate developments on Wednesday, having been reclassified as an AIM rule 15 cash shell.

Read more
28 Jan 2020 11:31

Motif Bio And Hercules Amend Agreement To Facilitate Iclaprim Sale

Motif Bio And Hercules Amend Agreement To Facilitate Iclaprim Sale

Read more
26 Nov 2019 18:15

Motif Bio To De-List From Nasdaq, Last Day Of Trading December 16

Motif Bio To De-List From Nasdaq, Last Day Of Trading December 16

Read more
18 Nov 2019 13:50

Five Motif Bio Non-Executive Directors Leave As Part Of Restructuring

Five Motif Bio Non-Executive Directors Leave As Part Of Restructuring

Read more
11 Nov 2019 09:52

Motif Bio Seals Clinical Research Firm Settlement Without Payments

Motif Bio Seals Clinical Research Firm Settlement Without Payments

Read more
11 Nov 2019 09:40

Motif Bio reaches settlement with former clinical research organisation

(Sharecast News) - Motif Bio announced on Monday that its subsidiary Motif BioSciences has reached an agreement with its former clinical research organisation to settle all obligations without further payment.

Read more
25 Oct 2019 17:34

Invesco Cuts Stake In Biopharmaceutifcal Firm Motif Bio To 8.4%

Invesco Cuts Stake In Biopharmaceutifcal Firm Motif Bio To 8.4%

Read more
24 Oct 2019 16:05

Motif Bio announces US Army-funded evaluation of 'iclaprim'

(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with 'iclaprim', to improve safety and efficacy administered by a novel enhanced aerosol technology, it announced on Thursday.

Read more
24 Oct 2019 12:01

Motif Bio Teams Up With US Forces To Look Into Iclaprim Use

Motif Bio Teams Up With US Forces To Look Into Iclaprim Use

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.